LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

Inicio・Lista de Acciones・Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals Inc

Cerrado

Sector Salud

4.16 5.85

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

4.08

Máximo

4.16

Métricas clave
By Trading Economics
Ingresos	3.3M -860K
Ventas	47M 94M
P/B Media del Sector	10.64 104.138
BPA	-0.01
Margen de beneficio	-0.911
Empleados	267
EBITDA	15M 27M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 meses	+168.5 upside

Dividendos
By Dow Jones
Próximas Ganancias	7 nov 2024

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	13M 648M
Apertura anterior	-1.69
Cierre anterior	4.16

Noticias sobre sentimiento de mercado

By Acuity

40%

60%

141 / 389 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

4.16 / 4.39 Soporte y Resistencia

Ironwood Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

1 nov 2024, 22:50 UTC

Acciones populares

Stocks to Watch: Nvidia, Intel, Sherwin-Williams, Dow, Nuwellis

1 nov 2024, 22:43 UTC

Principales Movimientos del Mercado

Nvidia, Sherwin-Williams Shares Up on Addition to DJIA

1 nov 2024, 22:13 UTC

Principales Movimientos del Mercado

Chewy Up 5% on S&P MidCap 400 Inclusion

1 nov 2024, 21:39 UTC

Ganancias

Insurance Company Chubb Projects Up to $300 Million Pre-Tax Loss on Hurricane

2 nov 2024, 13:53 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Warren Buffett's Berkshire Hathaway Slashes Apple Stake Again -- Update

2 nov 2024, 13:44 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Berkshire Sold 25% of Its Apple Stock in the Third Quarter -- Barrons.com

2 nov 2024, 13:00 UTC

Ganancias

China's EV Makers Set Sights on Latin America in Global Expansion -- WSJ

2 nov 2024, 12:58 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Berkshire Sold 25% of Its Apple Stock in the Third Quarter -- Barrons.com

2 nov 2024, 12:48 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Warren Buffett's Berkshire Hathaway Slashes Apple Stake Again -- WSJ

2 nov 2024, 12:32 UTC

Ganancias

Berkshire Profits Fell 6% in Third Quarter. The Buybacks Are on Pause. -- Barrons.com

2 nov 2024, 12:28 UTC

Adquisiciones, fusiones, absorciones

Berkshire Sold 25% of Its Apple Stock in the Third Quarter -- Barrons.com

2 nov 2024, 12:17 UTC

Ganancias

Berkshire Profits Fell 6% in Third Quarter. The Buybacks Are on Pause. -- Barrons.com

2 nov 2024, 12:00 UTC

Ganancias

Berkshire Hathaway 3Q EPS $18272.00 >BRKA

2 nov 2024, 12:00 UTC

Ganancias

Berkshire Hathaway 3Q BNSF Operating Earnings $1.38B >BRKA

2 nov 2024, 12:00 UTC

Ganancias

Berkshire Hathaway 3Q Berkshire Hathaway Energy Company Operating Earnings $1.63B >BRKA

2 nov 2024, 12:00 UTC

Ganancias

Berkshire Hathaway 3Q Insurance-Underwriting Operating Earnings $750M >BRKA

2 nov 2024, 12:00 UTC

Ganancias

Berkshire Hathaway 3Q Other Operating Loss $877M >BRKA

2 nov 2024, 12:00 UTC

Ganancias

Berkshire Hathaway 3Q Insurance-Investment Income Operating Earnings $3.66B >BRKA

2 nov 2024, 12:00 UTC

Ganancias

Berkshire Hathaway 3Q Net $26.25B >BRKA

2 nov 2024, 12:00 UTC

Ganancias

Berkshire Hathaway 3Q Other Controlled Businesses Operating Earnings $3.34B >BRKA

2 nov 2024, 12:00 UTC

Ganancias

Berkshire Hathaway 3Q Non-Controlled Businesses Operating Earnings $199M >BRKA

2 nov 2024, 12:00 UTC

Ganancias

Berkshire Hathaway 3Q Operating Earnings $10.09B >BRKA

2 nov 2024, 12:00 UTC

Ganancias

Berkshire Hathaway 3Q Investment, Derivative Gains $16.16B >BRKA

2 nov 2024, 09:30 UTC

Principales Noticias

Awful Jobs Report Aside, the Economy Is Still Strong -- Heard on the Street -- WSJ

2 nov 2024, 08:20 UTC

Charlas de Mercado

Ganancias

Tech, Media & Telecom Roundup: Market Talk

2 nov 2024, 08:20 UTC

Charlas de Mercado

Ganancias

Auto & Transport Roundup: Market Talk

1 nov 2024, 22:51 UTC

Ganancias

Correction to Nvidia to Replace Intel in Dow Jones Industrial Average Article -- WSJ

1 nov 2024, 22:00 UTC

Principales Noticias

Ganancias

Nvidia to Replace Intel in Dow Jones Industrial Average. Sherwin-Williams Also Joins. -- WSJ

1 nov 2024, 21:29 UTC

Principales Noticias

Ganancias

Exxon and Chevron Feel Brunt of Cheaper Oil -- 2nd Update

1 nov 2024, 21:24 UTC

Ganancias

Insurance Company Chubb Projects Up to $300M Pre-Tax Loss on Hurricane

Comparación entre iguales

Cambio de precio

Ironwood Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

168.5% repunte

Estimación a 12 meses

Media 11.25 USD 168.5%

Máximo 23 USD

Mínimo 5 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ironwood Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

5 ratings

Comprar

Mantener

Vender

De acuerdo con 5 analistas que ofrecen calificaciones bursátiles a para Ironwood Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

4.16 / 4.39Soporte y Resistencia

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

All events are bearish.

Sentimiento

By Acuity

141 / 389 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals, Inc. is a gastrointestinal (GI) healthcare company. The Company is focused on the development and commercialization of GI product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC). It operates in human therapeutics business segment. Its product candidate LINZESS (linaclotide) is available to adult men and women suffering from IBS-C or CIC in the United States, and Mexico and to adult men and women suffering from IBS-C in Japan and China. Its linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC in Canada, and to adult men and women suffering from IBS-C in certain European countries.